KKR Announces Intra-Quarter Monetization Activity Update for the Second Quarter
The estimate disclosed above is not intended to predict or represent total realized performance income, total realized investment income or total revenues for the full quarter ending June 30, 2025, because it does not include the results or impact of any other sources of income, including fee income, or expenses, and we may realize further gains or losses relating to total realized performance income and total realized investment income after the date of this press release. The estimate disclosed above is based on information available to us as of today with respect to the period from April 1, 2025 through June 20, 2025. This estimate is also not necessarily indicative of the results that may be expected for any other period, including the entire year ending December 31, 2025.
(1) This estimate is based on performance through the end of May.
About KKR
KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR's insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR's investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR's website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group's website at www.globalatlantic.com.
Forward-Looking Statements
This press release may contain forward-looking statements, including estimated operating results from certain monetization activities. Words such as 'expect,' 'estimate,' 'will,' 'may' and 'believe' or similar expressions may identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. Certain factors could cause actual results to differ materially from those included in these forward-looking statements, and investors should not place undue reliance on such statements. These forward-looking statements speak only as of the date of this press release, and we do not undertake any obligation to update or revise any of the forward-looking statements to reflect future events or circumstances, except as required by law.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Why Wolfe Research Sees More Downside Ahead for C3.ai (AI)
Inc. (NYSE:AI) is one of the . On August 11, Wolfe Research analyst Gal Munda reiterated an Underperform rating on the stock with a $15.00 price target. The rating affirmation follows the company's first quarter fiscal 2026 results. On Friday, the company reported that it sees preliminary revenue of $70.2 million-$70.4 million, an estimated 33% below the midpoint of its previous Q1 guidance for $100 million-$109 million. The adjusted operating loss will be $57.7 million-$59.9 million, almost twice as bad as the $23.5 million-$33.5 million loss that the company had expected. Company CEO Thomas Siebel said that sales results during the quarter were 'completely unacceptable' but driven by 'disruptive effect' of the reorganization and his ongoing health issues. Wolfe Research noted that it believes F1Q26 results have been a 'negative surprise that will likely drive shares materially lower despite the restructuring of the sales organization.' 'In July, the company announced a search for a successor to the CEO, and in the 8-K filing (link to filing here), it did not reiterate guidance, which we viewed as a risk to expectations. We believe F1Q26 results were a negative surprise that will likely drive shares materially lower despite the restructuring of the sales organization. Given the disappointing F1Q26 results, we believe FY26 revenue guidance could be revised significantly lower or potentially pulled entirely. Reiterate UP and $15 PT. ' Inc. (NYSE:AI) is an enterprise artificial intelligence (AI) software company involved in building and operating enterprise-scale AI applications and accelerating digital transformation. While we acknowledge the potential of AI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
35 minutes ago
- Business Wire
Consumer Rights Law Firm Hagens Berman Launches Investigation into Real Estate Agent Practices
SEATTLE--(BUSINESS WIRE)--Attorneys at national consumer-rights law firm Hagens Berman have initiated an investigation into real estate agent practices regarding home sale transactions. If we find that consumers were misled, we're prepared to act to hold companies responsible. Share The investigation comes on the heels of a blockbuster settlement totaling $1 billion in Burnett v. National Association of Realtors, which alleges that real estate brokerage companies and the National Association of Realtors caused home sellers to pay illegally inflated broker commissions through unlawful practices. Hagens Berman serves as co-lead counsel in the antitrust litigation. If you sold a home since 2021, you may be impacted by recently uncovered practices and could be eligible to potential compensation. Attorneys encourage those who have sold a home with the assistance of an online real estate agent since 2021 to contact the law firm to learn more about their rights. Real Estate's Real Cost Hagens Berman's research has identified allegedly deceptive practices in the home selling process that may affect consumers nationwide. Brokers, which offer home selling and buying services to millions across the U.S. each year, may be violating consumer rights and causing home sellers to overpay. 'Our investigation is about making sure the real estate market is fair and just for consumers,' says Steve W. Berman, managing partner of Hagens Berman and co-lead counsel in the recentlandmark real estate antitrust case. 'Buying or selling a home is one of the biggest financial decisions people make. Our job is to make sure families can trust the process and aren't taken advantage of. If we find that consumers were misled, we're prepared to act to hold companies responsible.' . About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation law firm with a tenacious drive for achieving real results for those harmed by corporate negligence and fraud. Since its founding in 1993, the firm's determination has earned it numerous national accolades, awards and titles of 'Most Feared Plaintiff's Firm,' MVPs and Trailblazers of class-action law. More about the law firm and its successes can be found at Follow the firm for updates and news at @ClassActionLaw.
Business Wire
35 minutes ago
- Business Wire
Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Therapeutics, Inc. ('Vyome'), a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that it has closed the previously disclosed transaction with ReShape Lifesciences Inc. (Nasdaq: RSLS). The post-merger company will trade at the open of trading on Friday, August 15, 2025 under the name Vyome Holdings, Inc. and the trading symbol 'HIND.' About Vyome Vyome is building a healthcare platform spanning the US-India innovation corridor. Based in Cambridge, MA, Vyome's immediate focus is leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety. To learn more, please visit Visit us on social media: Facebook X LinkedIn Forward-Looking Statements Certain statements made in this press release are 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as 'target,' 'believe,' 'expect,' 'will,' 'shall,' 'may,' 'anticipate,' 'estimate,' 'would,' 'positioned,' 'future,' 'forecast,' 'intend,' 'plan,' 'project,' 'outlook', and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Examples of forward-looking statements include, among others, statements made in this report regarding the merger, including the benefits of the merger, revenue opportunities, anticipated future financial and operating performance, and results, including estimates for growth. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vyome's control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, the following: (a) the occurrence of any event, change, or other circumstances relating to the combined company; (b) failure to obtain the necessary consents and approvals; (c) the risk that the merger disrupts current plans and operations as a result of the announcement and consummation of the merger; (e) costs related to the merger; and (f) changes in applicable laws or regulations. Vyome cautions that the foregoing list of factors is not exhaustive. Vyome cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Vyome does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, whether as a result of new information, future events, or otherwise, except as may be required by applicable law.
